por John R. Fischer
, Senior Reporter | September 07, 2023
BIOTRONIK's Amvia Edge pacemaker
The first implant of BIOTRONIK’s Amvia Edge pacemaker in the U.S. has been performed successfully in Miami.
Dr. Raul Weiss, a cardiologist and director of the William E. and Molly Ford Cardiac Electrophysiology Center at Mount Sinai Medical Center, placed the device within a patient, making it easier for them to undergo MR scanning in the future.
Here is a breakdown of the device’s core features:
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
- MRI Guard 24/7: MRI Guard 24/7, the device’s always-on MR sensor, automatically recognizes when a patient enters an MR field and converts the device to MR mode. Once out of the field, the device immediately returns to its permanent programming.
"The ability to eliminate device scans before and after an MR procedure is a much-needed advancement, and I look forward to seeing how these types of technologies help streamline our workflows in the future,” said Weiss in a statement.
- EarlyCheck: Automates pre-discharge checks and bypasses in-person device interrogations post-implant. EarlyCheck automatically sends a device report and intracardiac electrograms (IEGMs) to the BIOTRONIK Home Monitoring Service Center two hours after the procedure.
- QuickCheck: Provides remote transmissions that are available within minutes to healthcare professionals.
- Atrial ATP: Facilitates multiple, automatic therapies when stable atrial arrhythmias are detected, interrupting or treating atrial tachycardias or atrial fibrillation episodes to restore normal heart rhythm. This can help avoid or reduce atrial remodeling, decrease the risk of complications associated with prolonged atrial tachycardia, and improve quality of life.
- CLS: The only myocardial contractility sensor on the market, this feature continuously converts variations in myocardial contractility into physiologic pacing rate changes, aligning the heart’s pacing rate with the physiological needs of the patient, which is vital to heart health. Because of its no trade-off capabilities, physiological pacing rate adjustments can be made based on contractility and programming can be optimized without either aspect compromising the other.
It also uses closed-loop simulation to adjust timing differences between ventricular pacing pulses in the device by up to 30 milliseconds.
Amvia Edge was FDA approved in July.